vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman acquired 50,000 shares of vTv Therapeutics stock in a transaction on Thursday, August 22nd. The stock was purchased at an average cost of $1.38 per share, with a total value of $69,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

VTVT stock traded down $0.02 during trading on Thursday, reaching $1.37. The stock had a trading volume of 330,287 shares, compared to its average volume of 864,369. vTv Therapeutics Inc has a one year low of $0.68 and a one year high of $6.09. The company’s 50 day moving average is $1.37 and its two-hundred day moving average is $1.68. The company has a market capitalization of $69.83 million, a price-to-earnings ratio of -1.99 and a beta of -3.71.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.02. The firm had revenue of $1.83 million during the quarter, compared to the consensus estimate of $1.63 million. Equities research analysts anticipate that vTv Therapeutics Inc will post -0.53 EPS for the current year.

A number of equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of vTv Therapeutics in a research report on Friday, August 16th. ValuEngine downgraded shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, June 3rd. Zacks Investment Research downgraded shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Northland Securities reaffirmed a “buy” rating and issued a $8.00 price objective on shares of vTv Therapeutics in a research report on Thursday, August 1st.

A hedge fund recently raised its stake in vTv Therapeutics stock. BlackRock Inc. boosted its stake in vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 65,031 shares of the biotechnology company’s stock after buying an additional 13,305 shares during the period. BlackRock Inc. owned approximately 0.12% of vTv Therapeutics worth $93,000 at the end of the most recent quarter. 3.71% of the stock is currently owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Read More: What are different types of coverage ratios?

Insider Buying and Selling by Quarter for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.